CorMedix Q4 2022 Earnings Report $10.81 +0.51 (+4.95%) As of 04:00 PM Eastern Earnings HistoryForecast CorMedix EPS ResultsActual EPS-$0.20Consensus EPS -$0.19Beat/MissMissed by -$0.01One Year Ago EPSN/ACorMedix Revenue ResultsActual Revenue$0.03 millionExpected Revenue$0.01 millionBeat/MissBeat by +$20.00 thousandYoY Revenue GrowthN/ACorMedix Announcement DetailsQuarterQ4 2022Date3/30/2023TimeN/AConference Call ResourcesPress ReleaseCRMD Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by We recommended Palantir in 2021, now we’re recommending this... (Ad)I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nice stream of income along the way.Our research indicates ONE AI stock is poised to benefit the most. CorMedix Earnings HeadlinesCormedix: Strong Financial Outlook and Strategic Growth Initiatives Support Buy RatingJanuary 8 at 9:15 AM | markets.businessinsider.comCorMedix Inc. Preliminary Financial Results and Business Update (NASDAQ: CRMD)January 8 at 4:11 AM | americanbankingnews.comWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nice stream of income along the way.January 8, 2025 | Behind the Markets (Ad)CorMedix, Inc.: CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business UpdateJanuary 7 at 10:06 PM | finanznachrichten.deCormedix Buy Rating: Strong Sales Performance and Expanding Customer Base Signal Positive Growth ProspectsJanuary 7 at 10:06 PM | markets.businessinsider.comCorMedix up 22% at $9.66 in pre-market after Q4 revenue pre-announcementJanuary 7 at 10:06 PM | markets.businessinsider.comSee More CorMedix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CorMedix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CorMedix and other key companies, straight to your email. Email Address About CorMedixCorMedix (NASDAQ:CRMD), a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.View CorMedix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
